EP 1089736 A2 20010411 - METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION
Title (en)
METHOD AND COMPOSITIONS FOR THE TREATMENT OR AMELIORATION OF FEMALE SEXUAL DYSFUNCTION
Title (de)
METHODEN UND ZUSAMMENSTELLUNGEN ZUR BEHANDLUNG VON WEIBLICHER SEXUELLER DYSFUNKTION
Title (fr)
PROCEDE ET COMPOSITIONS POUR LE TRAITEMENT OU L'AMELIORATION DES DYSFONCTIONNEMENTS SEXUELS DE LA FEMME
Publication
Application
Priority
- CA 9900567 W 19990621
- US 10298798 A 19980622
Abstract (en)
[origin: WO9966909A2] The present invention provides a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation or diminished clitoral orgasm, or of combating vaginal pain by stimulating peripheral pelvic nerve release of nitric oxide (NO). The method comprises administering to a female in need of such treatment a therapeutically effective amount of a compound which acts on a mid-brain pathway to increase blood flow to the ilio-hypogastric-pudendal artery bed and stimulate the release of nitric oxide (NO) from peripheral NANC nerve cells. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs. Alternatively, the apomorphine is co-administered with an apomorphine-potentiating amount of an androgen, preferably testosterone either prior to, or concomitantly with, the administration of the apomorphine.
[origin: WO9966909A2] The present invention provide a method of treating sexual dysfunction in a female, including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished clitoral orgasm, or of combating vaginal pain. The preferred compound for the method of this invention is apomorphine or one of its pharmaceutically acceptable salts, esters, or pro-drugs. Other compounds are selected from the group consisting of (i) bromocriptine, lisuride, methergolide, pergolide, pribidil, guinapril; or (ii) 1-(2,5-dimethoxy-4-iodophenyl)-1-aminopropane, 5-methoxytryptamine, alpha-methyl-5-hydroxytryptamine, 2-methyl-5-hydroxytryptamine, N-acetyl-5-hydroxytryptamine, buspirone, sumatriptan; or (iii) isotocin, carbetocin, lysconopressin, deaminooxytocin, mesotocin, antocin, glumitocin, aspargitocin, valitocin, asvatocin, phasvatocin and seritocin. Alternatively, the apomorphine is co-administered with an apomorphine-potentiating amount of androgen, preferably testosterone either prior to, or concomitantly with, the administration of the apomorphine.
IPC 1-7
A61K 31/485; A61K 31/47; A61K 31/48; A61K 31/505; A61K 38/11; A61K 38/12; A61K 31/405; A61K 31/40
IPC 8 full level
A61K 31/137 (2006.01); A61K 31/4045 (2006.01); A61K 31/405 (2006.01); A61K 31/435 (2006.01); A61K 31/437 (2006.01); A61K 31/472 (2006.01); A61K 31/48 (2006.01); A61K 31/485 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/565 (2006.01); A61K 31/568 (2006.01); A61K 38/00 (2006.01); A61K 38/095 (2019.01); A61K 38/11 (2006.01); A61K 38/12 (2006.01); A61K 45/00 (2006.01); A61P 15/00 (2006.01); A61P 15/02 (2006.01)
CPC (source: EP)
A61K 31/4045 (2013.01); A61K 31/405 (2013.01); A61K 31/472 (2013.01); A61K 31/48 (2013.01); A61K 31/485 (2013.01); A61K 31/506 (2013.01); A61K 31/565 (2013.01); A61K 38/095 (2018.12); A61K 38/12 (2013.01); A61P 15/00 (2017.12); A61P 15/02 (2017.12)
Citation (search report)
See references of WO 9966909A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9966909 A2 19991229; WO 9966909 A3 20000629; AR 019694 A1 20020313; AU 4254799 A 20000110; CA 2334550 A1 19991229; EP 1089736 A2 20010411; JP 2002518435 A 20020625; MX PA01000275 A 20020424
DOCDB simple family (application)
CA 9900567 W 19990621; AR P990102966 A 19990622; AU 4254799 A 19990621; CA 2334550 A 19990621; EP 99957146 A 19990621; JP 2000555595 A 19990621; MX PA01000275 A 19990621